Member Info for EmeraldCarrots

Their Parsortix system is better, cheaper and faster than the best selling Cellsearch. Please check this out, I have.

Therefore there is a mangement problem.

Parsortix should be selling loads more. The "dual analysis" is a sales dream come true for Parsortix.

The board of Angle need to sort this out.

All IMHO.

System if you want to analyse the CTC's and especially if you want to perform DNA analysis. Illumina have been working with Angle and clearly see the huge potential for dual analysis. The sales side of Angle need to get their act together. There are obviously deals to be done. The sales side needs a complete overhaul. They only need a few contracts FFS!

System if you want to analyse the CTC's and especially if you want to perform DNA analysis. Illumina have been working with Angle and clearly see the huge potential for dual analysis. The sales side of Angle need to get their act together. There are obviously deals to be done. They need to get on with it.

GULP!!!!!!!!!!!!!

Jugs0.

"Big news out tomorrow, wouldnt want to be out of this for the news incoming!! Not long to wait for patient investors".

=========================

The "dual analysis" should become a big winner.

Illumina have recognised the potential, that is why they are working with Angle.

Angle's sales team should be very pleased how this has turned out.

i.e. Parsortix delivers a "label free" sample ideal for DNA analysis.

Cellsearch, the best seller, was designed primarily to count the number of CTC's, not catch them for analysis.

Cellsearch uses antibodies to help catch the CTC’s, so they are contaminated.

Therefore, Parsortix is the system to use if you want to analyse the CTC's.

Especially if you want to do DNA tests.

All IMHO.

1. CE certification for the Genedrive® CYP2C19.

2. A further five Group 2 hospitals phased to go-live from May 2025 for the Genedrive® MT-RNR1.

All due by end of May, which is of course is THIS WEEK.

Thurs?

1. Dual analysis. News about progress with Angle's liquid biopsy "dual analysis". That is combining the industry Std CtDna analysis (Dna analysis looking at fragments of DNA in the blood) with the Dna analysis of CTC's (circulating tumour cells) from the same tube of blood. The latter needs CTC's that are suitable for DNA analysis. Parsortix delivers CTC's that are alive and intact, so perfect for DNA analysis. Note dual analysis has been shown to find about twice the number of cancer biomarkers than CtDna analysis alone. Biomarkers can be targeted by modern cancer drugs so the poison is delivered directly to the cancer cells.

2. Dual analysis. Update on Angle/Illumina relationship. Both worked to create Illumina's lung cancer assay panel for dual analysis. Are there other panels in the pipeline, have any more been done? Will Angle be on Illumina's site? Maybe a section on Illumina's site for "Dual analysis" ?

3. Dual analysis. Where are we with the NuProbe assay panel option?

4. What other companies are Angle speaking to regarding dual analysis? It stands to reason any Company in the entire World that sells CtDna analysis should be talking to Angle plc and vice versa.

5. Her2 Bioview update.

6. More contracts with Astrazeneca?

7. Update on Bliss Pharma drug trial.

8. Sales of the Parsortix machine. The Parsortix machine delivers "label free" live and intact circulating tumour cells for analysis. That means they are not contaminated with antibodies etc. like other methods of capture. This makes them ideal for DNA analysis.

All IMHO.

Guy_incognito.

"You didn’t need to create a new thread to reply to me

The outgoings haven’t halved , they are spending around 500-600k a month , it’s actually insane at this point".

=============================================

From the half year report of 27th March 2025.

"The current level of operating expenditure is circa £0.5m per month, revenue and grant funding when received reducing the rate of cash burn.".

Since then, we have had many more new orders and the income from consumables continues to grow. It would not surprise me if the expenditure has halved by now.

Also, if their Chief Financial Officer is insane as you seem to suggest I think the other Directors would have noticed.

All IMHO.

RE: Guy_incognito.

That is incorrect. Check your facts.

Improve. We have?

1. CE certification for the Genedrive® CYP2C19. Clearly, they expect immediate orders from this. They have said as much.

2. A further five Group 2 hospitals phased to go-live from May 2025 for the Genedrive® MT-RNR1. So At least 5 more machines in use. So, 5 x the cost of each machine. Then the money for the consumables being at least from 14 machines (14 hospitals involved). Hospitals open 24/7 of course.

Assuming the income continues to improve they will eventually turn the corner.

- Outgoings steadily decreasing as the income increases. Money in bank lasting longer and longer.

Value of Genedrive Plc steadily increases.

All IMHO.

There were next to no orders. Almost nothing coming in. Now we have numerous hospitals using the machines, NHS Scotland placing orders and the Scottish Government singing Genedrive's praises. The cash situation will be a whole lot better than some on here would have you believe. Don’t forget the consumables that are needed every time the machines are used. Recent success and good publicity could easily tempt a buyer too. Any bidder could offer say 3p a share and rightly comment they are offering more than double the current price.

All IMHO.

Have anything positive to say?

1. CE certification for the Genedrive® CYP2C19.

2. A further five Group 2 hospitals phased to go-live from May 2025 for the Genedrive® MT-RNR1.

All due by end of May, which is of course is THIS WEEK.

Expected by some it seems!

2025 the trial will focus on high-risk patients, such as those who have had a mini-stroke or a minor stroke. The findings will help shape how genetic testing is used across the NHS in the future.". News due. The pilot should have ended 3 weeks ago.

Analysis. This is absolutely key for the future. Angle's "dual analysis" method absolutely needs live and intact CTC's to perform DNA analysis on the CTC's to find about DOUBLE the number of cancer biomarkers. Other systems that use antibodies to help catch the CTC's contaminate the samples. This is extremely important.

Than with Cellseach?

AI Overview

While Parsortix and CellSearch are both used for isolating circulating tumor cells (CTCs), DNA analysis might be easier with Parsortix due to its ability to capture a wider range of CTC phenotypes and potentially higher purity. Parsortix also offers a more streamlined process for harvesting and analyzing captured cells.

Parsortix:

Epitope-Independent:

Parsortix uses a size and deformability-based approach, meaning it doesn't rely on specific surface markers (epitopes) to capture CTCs, potentially capturing a broader range of phenotypes.

Potential for Higher Purity:

Some studies suggest Parsortix may offer a higher purity of captured CTCs compared to CellSearch, leading to cleaner DNA samples for analysis.

Ease of Harvesting:

Parsortix enables easy harvest of captured tumor cells, which can be further analyzed.

Wider Range of Mutations:

A study found a wider range of clinically relevant DNA mutations in CTCs isolated by Parsortix compared to ctDNA.

CellSearch:

Epitope-Dependent:

CellSearch relies on antibodies to capture CTCs, which means it might not be as effective at capturing cells that express low levels of EpCAM or have undergone epithelial-to-mesenchymal transition (EMT).

Capture of CK-Positive/Vimentin-Positive Cells:

CellSearch may not be as effective at capturing cells with both epithelial and mesenchymal markers.

Less Efficient Harvesting:

CellSearch may have less efficient harvesting of captured cells compared to Parsortix.

In essence: Parsortix offers a more versatile and potentially higher purity approach for isolating CTCs, which could simplify downstream DNA analysis by providing a richer and more easily manageable sample.

Main competitor. If they bought Angle Plc they would have a huge part of the circulating tumour cell (CTC) capture and analysis market.I believe The Menarini Group could bid for Angle, however they would be worried about a counter bid. Especially from Astrazeneca, Illumina or Thermo Fisher.

All IMHO.

Https://clinicaltrials.gov/study/NCT06967961?term=parsortix&rank=8

AI Overview

Flow Cytometry and CellSearch®, along with Flow Cytometry and Parsortix, are most commonly used for detecting circulating tumor cells (CTCs) in various types of cancers, particularly those with higher CTC numbers. CellSearch is FDA-cleared for specific uses in breast, prostate, and colorectal cancers. Parsortix offers advantages in recovering both epithelial and mesenchymal CTCs.

Here's a more detailed breakdown:

1. Tumor Types where CTCs are Detected:

Breast Cancer:

Both CellSearch and Parsortix have been used to identify and assess CTCs in metastatic breast cancer.

Prostate Cancer:

CellSearch is FDA-cleared for use in prostate cancer, including castration-resistant prostate cancer.

Colorectal Cancer:

Both CellSearch and Parsortix have been used to identify CTCs in colorectal cancer.

Other Cancers:

While CellSearch and Parsortix are most widely used for the above, CTC detection can be valuable in other cancers as well, including small cell lung cancer, non-small cell lung cancer, bladder cancer, pancreatic cancer, and head and neck cancer.

Limitations:

Some studies suggest that the detection of CTCs in certain gynecological tumors, neuroendocrine tumors, head and neck tumors, and melanoma may not be as successful due to factors like tumor-specific characteristics and the number of CTCs.

2. CellSearch vs. Parsortix:

CellSearch:

It uses a specific antibody-based approach to capture and detect epithelial CTCs in blood samples.

Parsortix:

It offers enhanced recovery of both epithelial and mesenchymal CTCs compared to CellSearch, making it valuable for studying CTCs in a wider range of cancers.

Downstream Analysis:

Both CellSearch and Parsortix allow for downstream molecular characterization of the captured CTCs.

1. CE certification for the Genedrive® CYP2C19.

2. A further five Group 2 hospitals phased to go-live from May 2025 for the Genedrive® MT-RNR1.

All due by end of May, which is of course next week!